Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage To be used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.
Marketing Status Prescription; Discontinued
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 48087-0113; 69238-1013; 49452-7652; 66887-004; 63629-2125; 0591-2114; 63629-2124; 0832-1120; 65089-0050; 63629-8455; 16714-967; 0603-7831; 0591-2363; 42667-5511; 49884-418; 82393-113; 24979-078; 76420-684; 43598-304; 38779-2598; 66887-001; 44132-008; 0832-1121; 64025-0010; 22552-0009; 0023-5990; 0051-8462; 38779-0163; 60870-0251; 45802-754; 70492-002; 51927-1026; 0591-2924; 71589-013; 0591-2921; 0591-2926; 51552-0029; 62332-488; 16714-968; 0245-0872; 44132-006; 0245-0871; 45802-366; 49452-7657; 0591-2925; 0051-8425; 76420-687; 68382-362; 76420-686; 0591-3216; 60592-721; 24979-130; 12875-8248; 45802-610; 76003-1083; 38779-2936; 0009-0074; 49884-510; 68180-943; 43647-568; 0051-8450; 0802-8068; 71589-011; 62991-2150; 69097-363; 0023-5992; 0009-5020; 0591-3524; 69339-158; 43742-1242; 76420-685; 70700-112; 68180-941; 63481-183; 43742-1436; 43742-0677; 63629-2352; 76420-699; 51552-0564; 16714-969; 0591-3217; 45802-281; 62332-552
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Heart disease congenital03.07.07.001; 02.01.01.009--Not Available
Heart rate decreased13.14.04.001--Not Available
Heart rate increased13.14.04.002--Not Available
Heart rate irregular13.14.04.0030.002375%Not Available
Hemiparesis17.01.04.0010.003859%
Hemiplegia17.01.04.0020.001188%Not Available
Hepatic adenoma16.06.01.002; 09.04.01.0020.000594%Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hepatic neoplasm09.04.03.001; 16.07.03.001--Not Available
Hepatitis toxic12.03.01.016; 09.01.07.0170.000891%Not Available
Hernia08.01.04.001--Not Available
High density lipoprotein decreased13.12.01.003--Not Available
Hirsutism23.02.04.001; 05.05.01.0050.000594%
Hostility19.05.01.003--Not Available
Hyperaesthesia17.02.06.0040.000594%Not Available
Hyperbilirubinaemia01.06.04.003; 14.11.01.010; 09.01.01.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hypercoagulation01.01.02.0070.001781%Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperkalaemia14.05.03.001--
Hyperkinesia17.01.02.008--Not Available
Hyperparathyroidism05.04.01.001--
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.05.02.012; 23.06.02.005; 10.02.02.017; 01.01.04.008--Not Available
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.001--Not Available
Hypertensive heart disease02.01.04.001; 24.08.05.0020.000465%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.0010.002078%
Hypertriglyceridaemia14.08.02.001--
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 26 Pages